Targeted therapies exist for the luminal and HER2+ (human epidermal growth factor receptor 2) subtypes of human breast cancers which significantly improve patient outcome by elimination of occult tumor cells through adjuvant therapies, thereby reducing the incidence of metastatic disease. Here, ERBB2 is linked to metastatic neoplasm.